IMA203 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: anzu-cel, anzutresgene autoleucel

Filter by location:

Phoenix, Arizona1 trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

San Francisco, California1 trial

ACTengine® IMA203 Combined With mRNA-4203

University of California San Francisco

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.